Biotech News

BioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026

BioCardia (BCDA)BioCardiaEarnings

BioCardia, Inc. [NASDAQ:BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the third quarter of 2026 by conference call on Thursday, November 12, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.

Related news

BioCardia

Cardiovascular Cell Therapy Company BioCardia develops cellular and cell-derived therapies for cardiovascular and pulmonary diseases. Its platform includes autologous CardiAMP and allogeneic CardiALLO cell therapies, supported by the Helix delivery and Morph vascular-navigation technologies. CardiAMP Heart Failure Program CardiAMP Cell...

Recent company news

Stock data

Close
0.77 USD
Market cap
10.24M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States